Choose the brand aligned with your industry so we can best serve your needs.
For researchers, scientists, and technical professionals: Your one-stop shop for the complete range of laboratory, production, and safety products and services.
Vipivotide tetraxetan is a DOTA-conjugated small-molecule ligand that selectively binds prostate-specific membrane antigen (PSMA) and is supplied as a research precursor for radiolabeling with diagnostic and therapeutic radionuclides. It is used in preclinical and clinical research for PSMA-targeted imaging and radioligand therapy.
DOTA-conjugated PSMA-targeting ligand suitable for radiolabeling with lutetium-177 or gallium-68.
High binding affinity for PSMA enabling targeted imaging and therapy applications.
Supplied with high purity (≈99.5%), appropriate for research use.
Available in multiple pack sizes, including 50 mg for synthesis and labeling workflows.
Useful as a precursor for developing PSMA-targeted radiopharmaceuticals.
Encompass Procurement Services Non-distribution item offered as a customer accommodation; additional freight charges may apply. Learn More
Zadavotide guraxetan is a prostate-specific membrane antigen (PSMA)-targeting small-molecule ligand used as a research precursor for PSMA-directed imaging and radioligand studies, including lutetium-177 conjugation. Intended for research use only.
PSMA-targeting ligand suitable for radiolabeling and imaging applications.
Reported high purity supports analytical and radiochemistry workflows.
Available as a solid in multiple pack sizes, including 100 mg.
CAS number 2192281-54-0 for unambiguous identification.
Molecular weight 1498.37 g/mol and chemical formula C63H92IN11O23.
Encompass Procurement Services Non-distribution item offered as a customer accommodation; additional freight charges may apply. Learn More